Navigation Links
DURECT Announces Resignation of Chief Medical Officer
Date:6/2/2011

CUPERTINO, Calif., June 2, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer, Chief Medical Officer and Executive Vice President, Corporate Strategy has resigned effective June 21, 2011 to pursue other opportunities.  Dr. Stauffer and DURECT have entered into a consulting agreement through December 31, 2011.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

"We appreciate all of Joe's efforts over the last two years, most notably in designing the U.S. pivotal Phase III clinical study for POSIDUR® (BESST), look forward to his continuing assistance through a consulting arrangement and wish him all the best in his future endeavors," stated James E. Brown, President and CEO.  "We are confident that the clinical and regulatory team we have in place will continue to execute in advancing our pipeline of programs in development."

"I enjoyed my time at DURECT and believe in the medical benefits of the company's pipeline," said Joseph Stauffer, D.O., M.B.A.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, and ELADUR™ are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Semrock’s highly popular SearchLight Spectra Viewer ... resource for fluorescence microscopists and optical system designers, enabling The Right Solution, Right ... the globe, SearchLight has become a tremendously popular tool for the fluorescence imaging ...
(Date:4/27/2017)... ... April 27, 2017 , ... Thinksport, the leaders in safe, ... award-winning sunscreen they’ve used the same scientific approach to solving smelly, sweaty athletes, ... the aisles that contain harmful chemicals that should be put nowhere near your ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Journal of ... It can have severe consequences to overall dental health, including complications with speech, eating, ... turn to dental implants to replace lost teeth. As the number of tooth replacements ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Excellence upon National Registry of Emergency Medical Technicians and welcomes this ... said Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at ...
Breaking Medicine News(10 mins):